These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32342332)

  • 1. Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma.
    Maggio D; Ho WS; Breese R; Walbridge S; Wang H; Cui J; Heiss JD; Gilbert MR; Kovach JS; Lu RO; Zhuang Z
    J Neurooncol; 2020 Jun; 148(2):231-244. PubMed ID: 32342332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
    Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
    J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.
    Ho WS; Wang H; Maggio D; Kovach JS; Zhang Q; Song Q; Marincola FM; Heiss JD; Gilbert MR; Lu R; Zhuang Z
    Nat Commun; 2018 May; 9(1):2126. PubMed ID: 29844427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
    Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
    Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
    Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
    Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
    Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
    Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
    Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.
    Kim JE; Patel MA; Mangraviti A; Kim ES; Theodros D; Velarde E; Liu A; Sankey EW; Tam A; Xu H; Mathios D; Jackson CM; Harris-Bookman S; Garzon-Muvdi T; Sheu M; Martin AM; Tyler BM; Tran PT; Ye X; Olivi A; Taube JM; Burger PC; Drake CG; Brem H; Pardoll DM; Lim M
    Clin Cancer Res; 2017 Jan; 23(1):124-136. PubMed ID: 27358487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
    Di Tacchio M; Macas J; Weissenberger J; Sommer K; Bähr O; Steinbach JP; Senft C; Seifert V; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Scheel AH; Büttner R; Grauer OM; Schittenhelm J; Tabatabai G; Harter PN; Günther S; Devraj K; Plate KH; Reiss Y
    Cancer Immunol Res; 2019 Dec; 7(12):1910-1927. PubMed ID: 31597643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
    Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
    Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
    Simonds EF; Lu ED; Badillo O; Karimi S; Liu EV; Tamaki W; Rancan C; Downey KM; Stultz J; Sinha M; McHenry LK; Nasholm NM; Chuntova P; Sundström A; Genoud V; Shahani SA; Wang LD; Brown CE; Walker PR; Swartling FJ; Fong L; Okada H; Weiss WA; Hellström M
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The N
    Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
    Front Immunol; 2021; 12():653711. PubMed ID: 34354698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.
    Ladomersky E; Zhai L; Lenzen A; Lauing KL; Qian J; Scholtens DM; Gritsina G; Sun X; Liu Y; Yu F; Gong W; Liu Y; Jiang B; Tang T; Patel R; Platanias LC; James CD; Stupp R; Lukas RV; Binder DC; Wainwright DA
    Clin Cancer Res; 2018 Jun; 24(11):2559-2573. PubMed ID: 29500275
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors.
    Hsu SPC; Chen YC; Chiang HC; Huang YC; Huang CC; Wang HE; Wang YS; Chi KH
    J Neurooncol; 2020 Feb; 146(3):417-426. PubMed ID: 32020472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma.
    Choi J; Medikonda R; Saleh L; Kim T; Pant A; Srivastava S; Kim YH; Jackson C; Tong L; Routkevitch D; Jackson C; Mathios D; Zhao T; Cho H; Brem H; Lim M
    Oncoimmunology; 2021; 10(1):1956142. PubMed ID: 34484870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
    Genoud V; Espinoza FI; Marinari E; Rochemont V; Dietrich PY; McSheehy P; Bachmann F; Lane HA; Walker PR
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.